Enteromedics Inc (ETRM) 1.21 $ETRM
EnteroMedics to Host Fourth Quarter 2014 Financial Results and Commercialization Update Conference Call
PR Newswire - Thu Feb 05, 11:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, February 18, 2015 at 11:00 AM Eastern Time to discuss financial results for the fourth quarter ended December 31, 2014 and to provide an update on the commercialization of the Company's VBLOC Therapy, delivered via the Maestro System.
ETRM: 1.21 (+0.06)
Despite the CDC's Best Efforts, This Disease Just Hit Record Levels
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 8:12AM CST
Source: Flickr user Next TwentyEight. Although cancer and heart disease may garner a significant portion of researchers' attention, obesity is a growing problem . According to estimates from the Centers for Disease Control and Prevention, more...
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), HWAY: 21.32 (+0.01), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
EnteroMedics to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Thu Jan 29, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 10:30 a.m. Eastern Time. The conference is being held at the Waldorf Astoria Hotel in New York City.
ETRM: 1.21 (+0.06)
Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
Spencer Osborne - at Seeking Alpha - Wed Jan 28, 10:49AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Newly Approved Weight Loss Method Works by Tricking Your Brain
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 25, 11:02AM CST
You can lose weight through plenty of methods. Dieting. Exercising. Taking weight-loss drugs. Undergoing gastric bypass surgery. The newest way, though, just might be the coolest and most revolutionary way of all. Source: EnteroMedics, ...
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics
at The Street - Fri Jan 23, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AGEN: 5.03 (-0.01), ETRM: 1.21 (+0.06), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), RCPT: 115.83 (-0.66), BMY: 60.04 (+0.56), ARNA: 4.55 (+0.02), NVS: 102.20 (-0.17)
Forget Pills! Could This Device Put an End to Obesity in America?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 17, 6:21AM CST
Source: Behavorial Risk Factor Surveillance Systems, Centers for Disease Control and Prevention. Obesity might be sometimes overlooked as a disease that needs immediate attention, but the reality is it's a serious condition that can lead to a...
OREX: 5.55 (+0.10), ZFGN: 39.06 (+0.92), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Enteromedics Garners FDA Approval For Obesity Device: What's Next
Spencer Osborne - at Seeking Alpha - Fri Jan 16, 11:36AM CST
ETRM: 1.21 (+0.06)
Lack of reimbursement will constrain obesity device sales
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 7:13AM CST
ETRM: 1.21 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 11:43AM CST
BEBE: 3.90 (+0.01), MDLY: 10.44 (-0.10), ZIOP: 9.64 (-0.35), GME: 37.35 (+0.10), FCX: 20.29 (+0.82), BGC: 14.40 (+0.51), HBM: 8.34 (+0.21), XON: 39.30 (+1.05), BBEP: 7.85 (+0.32), PES: 5.74 (+0.54), AAMC: 173.53 (-8.22), DWCH: 6.26 (-0.18), SMSI: 1.60 (+0.07), ETRM: 1.21 (+0.06), FLML: 14.15 (+0.15), EEI: 10.28 (-0.11), FCSC: 4.75 (+0.50), QURE: 19.83 (-0.18), ERII: 3.36 (+0.01), KONE: 4.20 (+0.03)
Stock to Watch: EnteroMedics Up 39.4% (ETRM)
Comtex SmarTrend(R) - Wed Jan 14, 10:35AM CST
EnteroMedics (NASDAQ:ETRM) is one of today's best performing low-priced stocks, up 39.4% to $1.65 on 20.0x average daily volume. Thus far today, EnteroMedics has traded 10.1 million shares, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (39.4% to the Dow's -1.4%) and outperformed the S&P 500 (39.4% to the S&P's -1.1%) during today's trading.
ETRM: 1.21 (+0.06)
FDA clears new obesity device
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 9:37AM CST
ETRM: 1.21 (+0.06)
EnteroMedics Announces FDA Approval of VBLOC® Vagal Blocking Therapy for the Treatment of Obesity
PR Newswire - Wed Jan 14, 9:36AM CST
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
ETRM: 1.21 (+0.06)
Stock to Watch: EnteroMedics Down 5.6% (ETRM)
Comtex SmarTrend(R) - Tue Jan 06, 11:35AM CST
EnteroMedics (NASDAQ:ETRM) is one of today's worst performing low-priced stocks, down 5.6% to $1.36 on 1.1x average daily volume. Thus far today, EnteroMedics has traded 520,000 shares, vs. average volume of 453,000 shares per day. The stock has underperformed the Dow (-5.6% to the Dow's -1.1%) and underperformed the S&P 500 (-5.6% to the S&P's -1.1%) during today's trading.
ETRM: 1.21 (+0.06)
Anticipated FDA Approval Eludes Enteromedics
Spencer Osborne - at Seeking Alpha - Mon Jan 05, 11:21AM CST
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Walgreens Investors' Final Nod for Alliance Boots Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 3:40PM CST
Walgreens' (WAG) partnership with Alliance Boots has been yielding positive results, with combined synergies reaching $140 million in first-quarter fiscal 2015.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), WAG: 76.05 (-0.49)
RTI Surgical Now a Strong Buy, Raised Guidance a Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 3:20PM CST
On Dec 30, 2014, Zacks Investment Research upgraded RTI Surgical Inc. (RTIX) to a Zacks Rank #1 (Strong Buy).
ETRM: 1.21 (+0.06), RTIX: 5.54 (+0.19), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32)
Cepheid's (CPHD) Xpert HIV Test Wins CE-IVD Mark in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 1:40PM CST
Cepheid's (CPHD) HIV viral load test is the standard measurement which is used in the diagnosis of HIV positive patients and helps in administering antiretroviral therapy.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72)
Sell EnteroMedics And Step To The Sidelines
Scientist on Stocks - at Seeking Alpha - Tue Dec 30, 11:25AM CST
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
EnteroMedics to Host Fourth Quarter 2014 Financial Results and Commercialization Update Conference Call
PR Newswire - Thu Feb 05, 11:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, February 18, 2015 at 11:00 AM Eastern Time to discuss financial results for the fourth quarter ended December 31, 2014 and to provide an update on the commercialization of the Company's VBLOC Therapy, delivered via the Maestro System.
ETRM: 1.21 (+0.06)
Despite the CDC's Best Efforts, This Disease Just Hit Record Levels
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 8:12AM CST
Source: Flickr user Next TwentyEight. Although cancer and heart disease may garner a significant portion of researchers' attention, obesity is a growing problem . According to estimates from the Centers for Disease Control and Prevention, more...
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), HWAY: 21.32 (+0.01), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
EnteroMedics to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Thu Jan 29, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 10:30 a.m. Eastern Time. The conference is being held at the Waldorf Astoria Hotel in New York City.
ETRM: 1.21 (+0.06)
Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
Spencer Osborne - at Seeking Alpha - Wed Jan 28, 10:49AM CST
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Newly Approved Weight Loss Method Works by Tricking Your Brain
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 25, 11:02AM CST
You can lose weight through plenty of methods. Dieting. Exercising. Taking weight-loss drugs. Undergoing gastric bypass surgery. The newest way, though, just might be the coolest and most revolutionary way of all. Source: EnteroMedics, ...
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics
at The Street - Fri Jan 23, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AGEN: 5.03 (-0.01), ETRM: 1.21 (+0.06), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), RCPT: 115.83 (-0.66), BMY: 60.04 (+0.56), ARNA: 4.55 (+0.02), NVS: 102.20 (-0.17)
Forget Pills! Could This Device Put an End to Obesity in America?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 17, 6:21AM CST
Source: Behavorial Risk Factor Surveillance Systems, Centers for Disease Control and Prevention. Obesity might be sometimes overlooked as a disease that needs immediate attention, but the reality is it's a serious condition that can lead to a...
OREX: 5.55 (+0.10), ZFGN: 39.06 (+0.92), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Enteromedics Garners FDA Approval For Obesity Device: What's Next
Spencer Osborne - at Seeking Alpha - Fri Jan 16, 11:36AM CST
ETRM: 1.21 (+0.06)
Lack of reimbursement will constrain obesity device sales
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 7:13AM CST
ETRM: 1.21 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 11:43AM CST
BEBE: 3.90 (+0.01), MDLY: 10.44 (-0.10), ZIOP: 9.64 (-0.35), GME: 37.35 (+0.10), FCX: 20.29 (+0.82), BGC: 14.40 (+0.51), HBM: 8.34 (+0.21), XON: 39.30 (+1.05), BBEP: 7.85 (+0.32), PES: 5.74 (+0.54), AAMC: 173.53 (-8.22), DWCH: 6.26 (-0.18), SMSI: 1.60 (+0.07), ETRM: 1.21 (+0.06), FLML: 14.15 (+0.15), EEI: 10.28 (-0.11), FCSC: 4.75 (+0.50), QURE: 19.83 (-0.18), ERII: 3.36 (+0.01), KONE: 4.20 (+0.03)
Stock to Watch: EnteroMedics Up 39.4% (ETRM)
Comtex SmarTrend(R) - Wed Jan 14, 10:35AM CST
EnteroMedics (NASDAQ:ETRM) is one of today's best performing low-priced stocks, up 39.4% to $1.65 on 20.0x average daily volume. Thus far today, EnteroMedics has traded 10.1 million shares, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (39.4% to the Dow's -1.4%) and outperformed the S&P 500 (39.4% to the S&P's -1.1%) during today's trading.
ETRM: 1.21 (+0.06)
FDA clears new obesity device
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 9:37AM CST
ETRM: 1.21 (+0.06)
EnteroMedics Announces FDA Approval of VBLOC® Vagal Blocking Therapy for the Treatment of Obesity
PR Newswire - Wed Jan 14, 9:36AM CST
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
ETRM: 1.21 (+0.06)
Stock to Watch: EnteroMedics Down 5.6% (ETRM)
Comtex SmarTrend(R) - Tue Jan 06, 11:35AM CST
EnteroMedics (NASDAQ:ETRM) is one of today's worst performing low-priced stocks, down 5.6% to $1.36 on 1.1x average daily volume. Thus far today, EnteroMedics has traded 520,000 shares, vs. average volume of 453,000 shares per day. The stock has underperformed the Dow (-5.6% to the Dow's -1.1%) and underperformed the S&P 500 (-5.6% to the S&P's -1.1%) during today's trading.
ETRM: 1.21 (+0.06)
Anticipated FDA Approval Eludes Enteromedics
Spencer Osborne - at Seeking Alpha - Mon Jan 05, 11:21AM CST
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Walgreens Investors' Final Nod for Alliance Boots Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 3:40PM CST
Walgreens' (WAG) partnership with Alliance Boots has been yielding positive results, with combined synergies reaching $140 million in first-quarter fiscal 2015.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), WAG: 76.05 (-0.49)
RTI Surgical Now a Strong Buy, Raised Guidance a Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 3:20PM CST
On Dec 30, 2014, Zacks Investment Research upgraded RTI Surgical Inc. (RTIX) to a Zacks Rank #1 (Strong Buy).
ETRM: 1.21 (+0.06), RTIX: 5.54 (+0.19), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32)
Cepheid's (CPHD) Xpert HIV Test Wins CE-IVD Mark in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 1:40PM CST
Cepheid's (CPHD) HIV viral load test is the standard measurement which is used in the diagnosis of HIV positive patients and helps in administering antiretroviral therapy.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72)
Sell EnteroMedics And Step To The Sidelines
Scientist on Stocks - at Seeking Alpha - Tue Dec 30, 11:25AM CST
OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
